
Parabilis Medicines, Inc.
89
Recent developments highlight Parabilis’ clinical progress with zolucatetide, financial results, leadership changes, and market activity.
- Parabilis reported a net loss of $44.5 million for Q3 2026, with basic and diluted EPS of -$0.36 per share, and revenue of $2.1 million for the quarter [N1][S1].
- The company reported a 72% response rate for zolucatetide in desmoid tumors and is planning a Phase III trial for 2027 [N2][N3].
- Parabilis has initiated a dose-ranging study for zolucatetide in treating familial adenomatous polyposis (FAP), with data expected by Q1 2027 [N4].
- Former Johnson & Johnson oncology executive Craig Tendler was named to Parabilis’ board, enhancing leadership expertise [N6].
- Parabilis stock has been noted among biotech stocks reaching 52-week highs in multiple reports during 2026 [N5][N7][N8].
Parabilis Medicines, Inc. is a clinical-stage biotechnology company focused on developing novel therapies using its proprietary Helicon discovery platform. The company’s lead product candidate, zolucatetide, is in clinical development for rare diseases including desmoid tumors and familial adenomatous polyposis (FAP). Parabilis has not yet achieved regulatory approval or commercial sales and has incurred significant net losses since inception. The company finances its operations through equity offerings, collaborations, and debt. As of September 30, 2026, Parabilis held substantial cash and short-term investments totaling approximately $872 million, supporting ongoing research and development activities. The company is progressing clinical trials, including a Phase III trial planned for 2027 for desmoid tumors and dose-ranging studies for FAP with data expected in early 2027.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Parabilis Medicines, Inc. is a clinical-stage biotechnology company developing novel biopharmaceuticals, with no approved products or commercial revenue. The company reported a net loss of $44.5 million for Q3 2026 and holds substantial liquidity of approximately $872 million as of September 30, 2026. Its lead candidate, zolucatetide, has shown a 72% response rate in desmoid tumors and is advancing toward a Phase III trial in 2027. The company is also conducting dose-ranging studies for FAP with data expected by early 2027. Parabilis faces typical clinical-stage biotech risks including regulatory, clinical, and commercialization uncertainties.
Parabilis has demonstrated promising clinical activity with zolucatetide, including a 72% response rate in desmoid tumors, supporting advancement to a Phase III trial. The company’s substantial liquidity provides runway to fund ongoing and planned clinical studies. Its proprietary Helicon platform and novel therapeutic approach could address unmet needs in rare diseases, potentially leading to differentiated products. Strategic collaborations and experienced leadership, including recent board additions, may enhance development and commercialization capabilities.
Parabilis faces significant risks inherent to clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes, regulatory approval challenges, and the absence of commercial products or revenues. The novel mechanisms of action and binding sites of its candidates may increase development complexity and regulatory scrutiny. The company’s continued net losses and high cash burn require sustained capital access, which may be affected by market conditions or clinical setbacks. Failure to obtain regulatory approvals or achieve market acceptance would materially harm the business.
Parabilis’ moat is primarily based on its proprietary Helicon discovery platform and its focus on novel mechanisms of action targeting rare diseases with unmet medical needs. The company’s lead candidate, zolucatetide, targets pathways with limited or no approved therapies, potentially offering differentiated treatment options. However, as a clinical-stage biotech company without approved products, its competitive advantage depends on successful clinical development, regulatory approval, and eventual commercialization. The company’s collaborations, including with Regeneron Pharmaceuticals, may provide strategic support but do not guarantee market exclusivity or commercial success.
• Clinical and Regulatory Risk: Parabilis has no approved products and its candidates require successful completion of clinical trials and regulatory approvals, which are uncertain and may be delayed or denied.
• Financial Risk: The company has incurred significant losses and depends on raising additional capital to fund operations. Failure to secure funding on acceptable terms could delay or halt development programs.
• Development Complexity: Novel mechanisms of action and binding sites may lead to unforeseen safety issues, increased development costs, or regulatory challenges.
• Commercialization Risk: Parabilis has no commercial infrastructure and must build or partner to market any approved products, which involves execution risks and uncertainties.
Business trends: Advancement of zolucatetide clinical trials including Phase III planning for desmoid tumors and dose-ranging studies for FAP; continued investment in Helicon platform and pipeline development.
Execution milestones: Completion of dose-ranging study data by Q1 2027; initiation and progress of Phase III desmoid tumor trial; potential regulatory submissions contingent on trial outcomes.
Key risks: Clinical trial and regulatory approval uncertainties; need for sustained capital to fund operations; challenges in manufacturing scale-up and commercialization; potential delays or failures in product development.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Parabilis Medicines, Inc. is a clinical-stage biotechnology company focused on developing biopharmaceutical products using its Helicon discovery platform.
- The company has no products approved for commercial sale and has not generated revenue from product sales to date.
- Its lead product candidate is zolucatetide, which is in clinical development for desmoid tumors and familial adenomatous polyposis (FAP).
- Parabilis reported a 72% response rate for zolucatetide in desmoid tumors and is planning a Phase III trial for this indication in 2027.
- The company has initiated a dose-ranging study for zolucatetide in treating FAP, with data expected by Q1 2027.
- As of September 30, 2026, Parabilis had $521.2 million in cash and cash equivalents and $350.4 million in short-term investments, totaling approximately $872 million in liquid assets.
- The company reported revenue of $2.1 million and a net loss of $44.5 million for Q3 2026, with basic and diluted EPS of -$0.36 per share.
- Parabilis had a current ratio of 12.88 and a cash ratio of 12.77 as of September 30, 2026, indicating strong liquidity.
- The company has incurred significant losses since inception, with an accumulated deficit of $683.8 million as of September 30, 2026.
- Parabilis finances its operations primarily through IPO proceeds, private placements, upfront payments from collaborations (notably with Regeneron Pharmaceuticals), convertible preferred stock sales, term loans, and SAFEs.
- The company faces risks typical of clinical-stage biotech firms, including uncertainty in clinical trial outcomes, regulatory approval, manufacturing scale-up, and commercialization capabilities.
- Parabilis' product candidates utilize novel mechanisms of action and binding sites, which may increase development complexity and regulatory scrutiny.
- The company expects to continue incurring significant expenses related to research, development, clinical trials, regulatory activities, and potential commercialization efforts.
- Parabilis named former Johnson & Johnson oncology executive Craig Tendler to its board, indicating strengthening of leadership expertise.
Generated 2026-11-15
- S1
- S1 | 2026-11-12 | 10-Q
- N1 | 2026-11-12 | www.nasdaq.com | Parabilis Medicines, Inc. Loss At -$44.491 Mln In Q3 | https://www.nasdaq.com/articles/parabilis-medicines-inc-loss-44491-mln-q3
- N2 | 2026-10-26 | www.nasdaq.com | Parabilis Medicines Reports 72% Response Rate For Zolucatetide In Desmoid Tumors; Stock Down | https://www.nasdaq.com/articles/parabilis-medicines-reports-72-response-rate-zolucatetide-desmoid-tumors-stock-down
- N3 | 2026-10-24 | www.nasdaq.com | Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027 | https://www.nasdaq.com/articles/parabilis-highlights-72-response-rate-maps-phase-iii-desmoid-trial-2027
- N4 | 2026-10-14 | www.nasdaq.com | Parabilis Begins Dose-Ranging Study For Zolucatetide In Treating FAP; Data By Q1 '27 | https://www.nasdaq.com/articles/parabilis-begins-dose-ranging-study-zolucatetide-treating-fap-data-q1-27
- N5 | 2026-09-18 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-mnov-36-pbls-10-abcl-9-hae-neo
- N6 | 2026-08-26 | www.nasdaq.com | Parabilis Medicines Names Former J&J Oncology Executive Craig Tendler To Board | https://www.nasdaq.com/articles/parabilis-medicines-names-former-jj-oncology-executive-craig-tendler-board
- N7 | 2026-08-18 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - OABI, IOVA, PBLS, RVMD, BLFS | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-oabi-iova-pbls-rvmd-blfs
- N8 | 2026-08-05 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-ufpt-25-infu-33-soph-20-q2-reports-repl-pbls
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


